Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures

Urotensin-II was originally isolated from the goby urophysis in the 1960s as a vasoactive peptide with a prominent role in cardiovascular homeostasis. The identification of human isoform of urotensin-II and its specific UT receptor by Ames et al. in 1999 led to investigating the putative role of the interaction U-II/UT receptor in multiple pathophysiological effects in humans. Since urotensin-II is widely expressed in several peripheral tissues including cardiovascular system, the design and development of novel urotensin-II analogues can improve knowledge about structure-activity relationships (SAR). In particular, since the modulation of the U-II system offers a great potential for therapeutic strategies related to the treatment of several diseases, like cardiovascular diseases, the research of selective and potent ligands at UT receptor is more fascinating. In this paper, we review the developments of peptide and nonpeptide U-II structures so far developed in order to contribute also to a more rational and detectable design and synthesis of new molecules with high affinity at the UT receptor.

[1]  S. Douglas,et al.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4–11) (UFP‐803) , 2006, British journal of pharmacology.

[2]  E. Novellino,et al.  Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta , 2003, British journal of pharmacology.

[3]  L. Mcmillan,et al.  2-Aminomethyl piperidines as novel urotensin-II receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[4]  U. Hacksell,et al.  Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). , 2002, Journal of medicinal chemistry.

[5]  U. Hacksell,et al.  Novel and potent small-molecule urotensin II receptor agonists. , 2009, Bioorganic & medicinal chemistry.

[6]  Hélène Castel,et al.  The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. , 2010, The Biochemical journal.

[7]  R. Carlton.  Z. , 1904, Industrial and Labor Relations Terms.

[8]  E. Novellino,et al.  Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. , 2005, Journal of medicinal chemistry.

[9]  Leonzio Rizzo,et al.  N , 1857, Notions d'histoire de la traduction.

[10]  Y. Hinokio,et al.  Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese , 2004, Peptides.

[11]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[12]  Terry Kenakin,et al.  Drug efficacy at G protein-coupled receptors. , 2002, Annual review of pharmacology and toxicology.

[13]  G. Warren,et al.  Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[14]  S. Salvadori,et al.  Structure–activity relationship study on human urotensin II , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[15]  Ettore Novellino,et al.  Unraveling the active conformation of urotensin II. , 2004, Journal of medicinal chemistry.

[16]  W. Marsden.  I and J , 2012 .

[17]  E. Novellino,et al.  Urotensin-II receptor antagonists. , 2006, Current medicinal chemistry.

[18]  A. Protopopov,et al.  Human ALY/BEF gene Map position 17q25.3 , 2004, Chromosome Research.

[19]  David G. Behm,et al.  Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375 , 2005, British journal of pharmacology.

[20]  R. Nishioka,et al.  Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Sarau,et al.  The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors , 2003, British journal of pharmacology.

[22]  Yi-Zhun Zhu,et al.  The role of urotensin II in cardiovascular and renal physiology and diseases , 2006, British journal of pharmacology.

[23]  E. Novellino,et al.  A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. , 2002, Journal of medicinal chemistry.

[24]  E. Kostenis,et al.  A new ligand for the urotensin II receptor , 2002, British journal of pharmacology.

[25]  A. Colton.  Effective thermal parameters for a heterogeneous land surface , 1996 .

[26]  U. Hacksell,et al.  Isochromanone-based urotensin-II receptor agonists. , 2005, Bioorganic & medicinal chemistry.

[27]  H. Sarau,et al.  The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems , 2006, British journal of pharmacology.

[28]  アーノルド，アン，ロマニック,et al.  Human urotensin ii , 1999 .

[29]  B. Maryanoff,et al.  Generation of novel, potent urotensin-II receptor antagonists by alkylation-cyclization of isoindolinone C3-carbanions , 2009 .

[30]  H. Vaudry,et al.  A proenkephalin A-derived peptide analogous to bovine adrenal peptide E from frog brain: Purification, synthesis, and behavioral effects , 1996, Peptides.

[31]  A. Islam.  [U] , 1957, The Country Houses of Shropshire.

[32]  R. Nishioka,et al.  Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. , 1985, Recent progress in hormone research.

[33]  N. Hazon,et al.  Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. , 1996, The Journal of experimental zoology.

[34]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[35]  R. Jensen,et al.  Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues. , 1993, Molecular pharmacology.

[36]  Hassan Oulyadi,et al.  Structure–activity relationships and structural conformation of a novel urotensin II-related peptide , 2004, Peptides.

[37]  Ralph Hirschmann,et al.  Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor. , 2006, Organic letters.

[38]  M. Clozel,et al.  Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System , 2004, Journal of Pharmacology and Experimental Therapeutics.

[39]  H. Sarau,et al.  Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). , 2005, Biochemical pharmacology.

[40]  H. Vaudry,et al.  Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda. , 1992, Biochemical and biophysical research communications.

[41]  S. Douglas,et al.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. , 2000, Trends in cardiovascular medicine.

[42]  N. Aiyar,et al.  Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines , 2004, British journal of pharmacology.

[43]  A. Davenport,et al.  Is urotensin‐II the new endothelin? , 2002, British journal of pharmacology.

[44]  アンダーソン，エリツク・シー,et al.  Phenylenediamine urotensin -ii receptor antagonist and ccr-9 antagonists , 2004 .

[45]  M. Shichiri,et al.  Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues , 2001, Journal of hypertension.

[46]  Thomas de Quincey.  [C] , 2000, The Works of Thomas De Quincey, Vol. 1: Writings, 1799–1820.

[47]  E. Novellino,et al.  Endogenous Urotensin II Selectively Modulates Erectile Function through eNOS , 2012, PloS one.

[48]  A. Davenport,et al.  Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1 , 2000, British journal of pharmacology.

[49]  M. Létourneau,et al.  Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. , 2012, Biochemical pharmacology.

[50]  N. Aiyar,et al.  Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. , 2004, European journal of pharmacology.

[51]  S. Douglas,et al.  Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease , 2006, Peptides.

[52]  T. Deguchi,et al.  Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-alpha and -gamma , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  H. Almond,et al.  Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment. , 2007, Bioorganic & medicinal chemistry letters.

[54]  C. Yu,et al.  NMR spectra and restrained molecular dynamics of the mushroom toxin viroisin. , 2009, International journal of peptide and protein research.

[55]  J. Rivier,et al.  Characterization of the biologically and antigenically important regions of urotensin II. , 1986, Proceedings of the Western Pharmacology Society.

[56]  Patricia Andrade-Gordon,et al.  Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. , 2002, Angewandte Chemie.

[57]  T. Klabunde,et al.  Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.

[58]  K. Mori,et al.  The olfactory bulb: coding and processing of odor molecule information. , 1999, Science.

[59]  Nobuyuki Miyajima,et al.  Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. , 2003, Biochemical and biophysical research communications.

[60]  N. Aiyar,et al.  Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey , 2002, British journal of pharmacology.

[61]  U. Hacksell,et al.  Design, parallel synthesis and SAR of novel urotensin II receptor agonists. , 2007, European journal of medicinal chemistry.

[62]  H. Vaudry,et al.  Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts , 2006, Peptides.

[63]  Ettore Novellino,et al.  Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues. , 2002, Bioorganic & medicinal chemistry.

[64]  Yumiko Saito,et al.  Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction , 1999, Nature Cell Biology.

[65]  Peter Gluchowski,et al.  F , 1934, The Herodotus Encyclopedia.

[66]  C. Reynolds,et al.  Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. , 2009, Journal of medicinal chemistry.

[67]  D. Vieau,et al.  A Second Somatostatin Gene is Expressed in the Brain of the Frog Rana ridibunda , 1998, Annals of the New York Academy of Sciences.

[68]  David G. Behm,et al.  Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist , 2002, British journal of pharmacology.

[69]  Oliver Bendel.  [E] , 1896, Les noms officiels des communes de Wallonie, de Bruxelles-Capitale et de la communaute germanophone.

[70]  S. Douglas,et al.  N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[71]  D. Behm,et al.  Aminomethylpiperazines as selective urotensin antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[72]  D. Behm,et al.  Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. , 2004, European journal of pharmacology.

[73]  N. Aiyar,et al.  Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues , 2008, British journal of pharmacology.

[74]  E. Novellino,et al.  Urotensin-II receptor ligands. From agonist to antagonist activity. , 2005, Journal of medicinal chemistry.

[75]  J. Taylor,et al.  Structural requirements at the N-terminus of urotensin II octapeptides , 2002, Peptides.